LifeMD Reports Revenue Decline and Increased Operating Losses in Q2 2026

LifeMD, Inc. reported its financial results for the second quarter of 2026, revealing a decline in revenue and an increase in operating losses compared to the same period in 2025. The company generated $47.3 million in telehealth revenue for the three months ended June 30, 2026, a decrease of 4% from $49.0 million in the prior year. For the first half of 2026, total revenue was approximately $97.4 million, down 2% from $99.9 million in the same period of 2025. The decrease in revenue was primarily attributed to a decline in telehealth product sales, which fell by approximately $2 million due to reduced online demand.

Despite the revenue decline, LifeMD's gross profit for the second quarter remained relatively stable at $42.0 million, with a gross margin of 89%, up from 86% in the previous year. The cost of telehealth revenue decreased significantly by 23% to $5.3 million, reflecting a favorable product mix and lower shipping costs. However, total operating expenses increased by 10% to $49.1 million, driven largely by a 27% rise in selling and marketing expenses, which amounted to $28.0 million as the company ramped up initiatives to drive future sales growth.

LifeMD's net loss from continuing operations for the second quarter was $7.1 million, compared to a loss of $2.3 million in the same quarter of 2025. The net loss attributable to common stockholders was $7.9 million, resulting in a basic loss per share of $0.16, compared to a loss of $0.05 per share in the prior year. The company also reported an accumulated deficit of approximately $246.1 million as of June 30, 2026, and a negative working capital of $4.5 million, indicating ongoing financial challenges.

In terms of operational metrics, LifeMD served approximately 356,000 active patient subscribers as of June 30, 2026, with a total of over 1.55 million patients served since inception. The company continues to expand its telehealth offerings, including a recently launched GLP-1 Weight Management Program and a virtual primary care service. LifeMD's strategic focus remains on enhancing its integrated telehealth platform, which combines technology, clinical services, and pharmacy infrastructure to deliver comprehensive care.

Looking ahead, LifeMD expects its existing cash balance of $25.1 million and potential proceeds from its At Market Issuance Sales Agreement will be sufficient to fund its operations and capital expenditures for at least the next 12 months. The company is also working to address material weaknesses in its internal controls over financial reporting, which have been identified as a risk factor in its operations.